Search

Your search keyword '"Zammit, Valentina"' showing total 17 results
Start Over Author "Zammit, Valentina"
17 results on '"Zammit, Valentina"'

5. BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

Author

Pennisi, Maria Stella, primary, Stella, Stefania, additional, Vitale, Silvia Rita, additional, Puma, Adriana, additional, Di Gregorio, Sandra, additional, Romano, Chiara, additional, Tirrò, Elena, additional, Massimino, Michele, additional, Antolino, Agostino, additional, Siragusa, Sergio, additional, Mannina, Donato, additional, Impera, Stefana, additional, Musolino, Caterina, additional, Mineo, Giuseppe, additional, Martino, Bruno, additional, Zammit, Valentina, additional, Di Raimondo, Francesco, additional, Manzella, Livia, additional, Stagno, Fabio, additional, and Vigneri, Paolo, additional

Published
2019
Full Text
View/download PDF

6. Rapid decline of Philadelphia‑positive metaphases after nilotinib treatment in a cml patient expressing a rare e14a3 bcr‑abl1 fusion transcript: A case report

Author

Massimino, Michele, primary, Stella, Stefania, additional, Tirr�, Elena, additional, Consoli, Maria, additional, Pennisi, Maria, additional, Puma, Adriana, additional, Vitale, Silvia, additional, Romano, Chiara, additional, Zammit, Valentina, additional, Stagno, Fabio, additional, Di Raimondo, Francesco, additional, and Manzella, Livia, additional

Published
2019
Full Text
View/download PDF

7. Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)

Author

TIRRÒ, ELENA, primary, MASSIMINO, MICHELE, additional, STELLA, STEFANIA, additional, ZAMMIT, VALENTINA, additional, CONSOLI, MARIA LETIZIA, additional, PENNISI, MARIA STELLA, additional, VITALE, SILVIA RITA, additional, ROMANO, CHIARA, additional, PIROSA, MARIA CRISTINA, additional, MARTINO, ENRICA, additional, DI GREGORIO, SANDRA, additional, PUMA, ADRIANA, additional, DI RAIMONDO, FRANSCESCO, additional, MANZELLA, LIVIA, additional, and STAGNO, FABIO, additional

Published
2019
Full Text
View/download PDF

8. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report

Author

MASSIMINO, MICHELE, primary, STELLA, STEFANIA, additional, TIRRÒ, ELENA, additional, CONSOLI, MARIA LETIZIA, additional, PENNISI, MARIA STELLA, additional, PUMA, ADRIANA, additional, VITALE, SILVIA RITA, additional, ROMANO, CHIARA, additional, ZAMMIT, VALENTINA, additional, STAGNO, FABIO, additional, DI RAIMONDO, FRANCESCO, additional, and MANZELLA, LIVIA, additional

Published
2019
Full Text
View/download PDF

9. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

Author

Stella, Stefania, primary, Zammit, Valentina, additional, Vitale, Silvia Rita, additional, Pennisi, Maria Stella, additional, Massimino, Michele, additional, Tirrò, Elena, additional, Forte, Stefano, additional, Spitaleri, Antonio, additional, Antolino, Agostino, additional, Siracusa, Sergio, additional, Accurso, Vincenzo, additional, Mannina, Donato, additional, Impera, Stefana, additional, Musolino, Caterina, additional, Russo, Sabina, additional, Malato, Alessandra, additional, Mineo, Giuseppe, additional, Musso, Maurizio, additional, Porretto, Ferdinando, additional, Martino, Bruno, additional, Di Raimondo, Francesco, additional, Manzella, Livia, additional, Vigneri, Paolo, additional, and Stagno, Fabio, additional

Published
2019
Full Text
View/download PDF

10. Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report

Author

Tirrò, Elena, primary, Stella, Stefania, additional, Massimino, Michele, additional, Zammit, Valentina, additional, Pennisi, Maria Stella, additional, Vitale, Silvia Rita, additional, Romano, Chiara, additional, Di Gregorio, Sandra, additional, Puma, Adriana, additional, Di Raimondo, Francesco, additional, Stagno, Fabio, additional, and Manzella, Livia, additional

Published
2019
Full Text
View/download PDF

11. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma

Author

Milone, Giuseppe, primary, Martino, Massimo, additional, Leotta, Salvatore, additional, Spadaro, Andrea, additional, Zammit, Valentina, additional, Cupri, Alessandra, additional, Avola, Giuseppe, additional, Camuglia, Maria Grazia, additional, Di Marco, Annalia, additional, Scalzulli, Potito, additional, Morelli, Mara, additional, Olivieri, Attilio, additional, and Tripepi, Giovanni, additional

Published
2017
Full Text
View/download PDF

12. Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.

Author

Tirrò, Elena, Stella, Stefania, Massimino, Michele, Zammit, Valentina, Pennisi, Maria Stella, Vitale, Silvia Rita, Romano, Chiara, Di Gregorio, Sandra, Puma, Adriana, Di Raimondo, Francesco, Stagno, Fabio, and Manzella, Livia

Abstract

BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations. Nevertheless, several patients co-expressing the JAK2V617F mutation and the BCR-ABL1 transcript have been described in the literature. We report the case of a 61-year-old male who presented with an essential thrombocythaemia phenotype and had a subsequent diagnosis of chronic phase chronic myeloid leukaemia. Colony-forming assays demonstrated the coexistence of 2 different haematopoietic clones: one was positive for the JAK2V617F mutation and the other co-expressed both JAK2V617F and the BCR-ABL1 fusion gene. No colonies displayed the BCR-ABL1 transcript alone. These findings indicate that the JAK2V617F mutation was the founding genetic alteration of the disease, followed by the acquisition of the BCR-ABL1 chimeric oncogene. Our data support the hypothesis that a heterozygous JAK2V617F clone may have favoured the bi-clonal nature of this myeloproliferative disorder, generating clones harbouring a second transforming genetic event. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma

Author

Milone, Giuseppe, primary, Martino, Massimo, additional, Di Marco, Annalia, additional, Leotta, Salvatore, additional, Spadaro, Andrea, additional, Morelli, Mara, additional, Avola, Giuseppe, additional, Camuglia, Maria Grazia, additional, Cupri, Alessandra, additional, Zammit, Valentina, additional, Scalzulli, Potito Rosario, additional, Valeria, Calafiore, additional, Olivieri, Attilio, additional, and Tripepi, Giovanni, additional

Published
2015
Full Text
View/download PDF

14. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.

Author

Milone, Giuseppe, Martino, Massimo, Leotta, Salvatore, Spadaro, Andrea, Zammit, Valentina, Cupri, Alessandra, Avola, Giuseppe, Camuglia, Maria Grazia, Di Marco, Annalia, Scalzulli, Potito, Morelli, Mara, Olivieri, Attilio, and Tripepi, Giovanni

Subjects
MULTIPLE myeloma treatment, MULTIPLE myeloma, CANCER chemotherapy, STEM cell transplantation, CYCLOPHOSPHAMIDE, PATIENTS
Abstract

We here report final results of a phase II/III prospective study that evaluated in Multiple Myeloma the use of on-demand plerixafor (PLX) added to mobilizing chemotherapy for patients showing predictive signs of mobilization failure. A total of 111 patients with MM were registered, all received cyclophosphamide 4 g/m2and granulocyte colony-stimulating factor (G-CSF). Overall, a successful CD34+ cell mobilization was achieved in 97.2% (108/111) of patients. Minimum harvest (≥2.0 × 106CD34+ cells/kg) was achieved in 97.2% (108/111) and optimal harvest success (≥4.0 × 106CD34+ cells/kg) was achieved in 84.6% (94/111). Multivariate analysis showed that patients who received on-demand PLX treatment had significantly higher likelihoods of successfully achieving both the minimal (p = .006) and optimal harvest (p = .05) in respect to a historical control group mobilized without any PLX. The incremental cost-effectiveness ratio, for each 1% increase in probability of achieving a successful minimal harvest, was€40.6 per patient. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

15. Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review

Author

Malato, Alessandra, Saccullo, Giorgia, Coco, Lucio Lo, Mancuso, Salvatrice, Santoro, Marco, Martino, Samuela, Zammit, Valentina, Sprini, Delia, Siragusa, Sergio, Malato, A, Saccullo, G, Lo Coco, L, Mancuso, S, Santoro, M, Martino, S, Zammit, V, Sprini, D, and Siragusa, S

Subjects
Male, Mutation, Hemoglobinuria, Paroxysmal, Humans, Membrane Proteins, Female, Thrombosis, Review, EPN, Settore MED/15 - Malattie Del Sangue
Published
2012

16. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study

Author

Stefania Paolini, Felicetto Ferrara, Francesco Di Raimondo, Axel Visani, Federica Loscocco, Valentina Zammit, Marco B. L. Rocchi, Eleonora Spina, Giuseppe Visani, Alessandro Isidori, Fabio Fuligni, Pier Paolo Piccaluga, Visani, Giuseppe, Ferrara, Felicetto, Di Raimondo, Francesco, Loscocco, Federica, Fuligni, Fabio, Paolini, Stefania, Zammit, Valentina, Spina, Eleonora, Rocchi, Marco, Visani, Axel, Piccaluga, Pier Paolo, and Isidori, Alessandro

Subjects
Myeloid, Oncology, Male, Cancer Research, Phases of clinical research, Elderly, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Clinical endpoint, Complete remission, Lenalidomide, Aged, 80 and over, Tumor, Leukemia, Hematology, Cytarabine, Myeloid leukemia, Thalidomide, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Human, medicine.drug, Low-dose therapy, Unfit, medicine.medical_specialty, Acute, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Biomarkers, Tumor, Humans, Aged, Acute myeloid leukemia, Antineoplastic Combined Chemotherapy Protocol, business.industry, Gene Expression Profiling, Induction chemotherapy, Biomarker, Gene expression profile, Transcriptome, Surgery, business, Biomarkers, 030215 immunology
Abstract

Outcome for elderly patients with acute myeloid leukemia (AML) is extremely poor. Intensive induction chemotherapy is often unsuitable. Sixty-six newly diagnosed AML patients (median age: 76 years), ineligible for standard therapy, were consecutively treated with low-dose lenalidomide (10 mg/day orally, days 1–21) plus 10 mg/m2low-dose cytarabine, subcutaneously, twice a day (days 1–15) every six weeks, up to 6 cycles. Complete remission (CR) rate was 36.3% according to intention-to-treat. Responding patients had a longer median overall survival than non-responders (517 vs. 70 days, P < 0.001). The achievement of CR was not predicted by bone marrow blast count, cytogenetics, molecular markers, prior MDS, white blood cell count. Conversely, by studying the global gene expression profile, we identified a molecular signature, including 309 genes associated with clinical response (CR versus no CR). Based on the expression of a minimal set of 16 genes, we developed an algorithm to predict treatment response, that was successfully validated by showing an overall accuracy of 88%. We met the primary endpoint of the study, by beating the estimated successful CR rate (P1) fixed at 30%. Moreover, CR induced by this 2-drug combo was efficiently predicted by genetic profiling, identifying a biomarker that warrants validation in independent series.

Published
2017

17. Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review.

Author

Malato A, Saccullo G, Coco LL, Mancuso S, Santoro M, Martino S, Zammit V, Sprini D, and Siragusa S

Subjects
Female, Humans, Male, Membrane Proteins genetics, Membrane Proteins metabolism, Mutation, Hemoglobinuria, Paroxysmal etiology, Hemoglobinuria, Paroxysmal genetics, Hemoglobinuria, Paroxysmal metabolism, Thrombosis complications, Thrombosis genetics, Thrombosis metabolism
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results